Ipsen jumps in­to the TCR space, team­ing with start­up helmed by for­mer Mer­ck KGaA can­cer chief

Ipsen is con­tin­u­ing its deal­mak­ing ways to kick off the new month, shelling out a hand­some $45 mil­lion up­front to a TCR up­start Mon­day morn­ing.

The French phar­ma com­pa­ny is part­ner­ing with Maren­go Ther­a­peu­tics on two ex­per­i­men­tal drugs, with the biotech tak­ing on pre­clin­i­cal work and Ipsen plan­ning to run the clin­i­cal stud­ies. And the pay­off for Maren­go could be huge — Ipsen is promis­ing near­ly $1.6 bil­lion in mile­stones if both pro­grams hit all of their goals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER